期刊文献+

补肾益气扶正汤辅助治疗肾癌患者术后应用重组人干扰素α2b产生的不良反应疗效观察 被引量:6

Study on the effficacy of Bushen Yiqifuzheng tang in treatment of adverse effects of recombinant human interferon α2b applied in post-operative patients with renal cancer
下载PDF
导出
摘要 目的探讨中药补肾益气扶正汤辅助治疗肾癌患者术后应用重组人干扰素α2b产生的不良反应的临床疗效。方法随机选取2010年1月至2015年2月住院治疗的肾癌患者96例,并将其随机平均分成实验组和对照组,对照组患者在手术后的第14天开始给予重组人干扰素α2b免疫治疗,而实验组在对照组的基础上再口服自拟中药补肾益气扶正汤辅助治疗,3个月后对比两组患者的患者全身状况、病情变化情况以及不良反应发生情况。结果治疗后,实验组患者的行为状况要明显优于对照组,流感样及消化道、神经精神系统症状、血细胞减少等相关不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论肾癌患者应用重组人干扰素α2b+补肾益气扶正汤联合治疗能够很好地改善患者的全身状况,降低相关不良反应的发生率,具有明显临床治疗效果,值得在临床工作中应用。 Objective To evaluate the role of Bushen Yiqifuzheng tang in treatment of adverse effects of recombinant human interferonα2b in postoperative patients with renal cancer. Methods Ninety - six patients with renal cancer treated in this hospital during January 2010 to February 2015 were involved in this present study. These patients were randomly divided into experimental group and control group. Patients in control group and experimental group received the treatment of recombinant human interferon α2b for 14 days after operation,and patients in exper-imental group were simultaneously received Bushen Yiqi Fuzheng tang for supplementary treatment. The general conditions of patients and adverse reactions were evaluated during the 3 - month follow - up period. Results After treatment for three months,the general condition of patients in experimental group was significantly better than that of patients in control group. Patients in experimental group got benefits on less flu - like symp-toms,less digestive symptoms,less neuropsychiatric symptoms and less reduction of blood cells,and the difference between these two groups was statistically significant( P 〈 0. 05). Conclusion The application of Bushen Yiqifuzheng tang can improve the general condition of patients with renal cancer received post - operative recombinant human interferon α2b by reducing flu - like symptoms,digestive symptoms,neuropsychiatric symptoms and reduction of blood cells,thus it suggests its potential for clinical application.
作者 勾善军
出处 《临床和实验医学杂志》 2016年第11期1045-1047,共3页 Journal of Clinical and Experimental Medicine
基金 2015年河北省承德市科学技术研究与发展计划项目(编号:20157100)
关键词 肾癌 补肾益气扶正汤 重组人干扰素Α2B 不良反应 Renal cancer Bushenyiqifuzhengtang Recombinant human interferon α2b Adverse reactions
  • 相关文献

参考文献7

二级参考文献49

  • 1宋希双,何中舟,殷积斌,张仁科,车翔宇,王建伯.中、晚期肾癌的介入、手术和生物联合治疗[J].中华外科杂志,2004,42(23):1450-1452. 被引量:7
  • 2廖新媛 唐新德 曾凡波.虎杖中大黄素抗肿瘤药理研究.中国医院药学杂志,1998,18(5):214-215.
  • 3Wedgwood S,Dettman RW,Black S H. ET-1 stimulate plllmollal" yarterial smooth muscle cell proliferation viain ducfion of reaction oxygen species[ J ]. Am J Phsiolng Cell Mol Physiol, 2001,281 (22) :1058:271-278.
  • 4Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasOpharyngeaI carcinoma:results of a meta-analysis of 1. 528 patients from six randomized trials. Am J Clin OncoI. 2002,19 (25) :219-223.
  • 5Kondo K, Yao M, Yoshida M, etal. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters[J]. Genes Chromosomes Cancer,2002,34(l) :58-68.
  • 6Sudrez C, Morales R, Munoz E, et al. Molecular basis for the treatment of renal cell carcinoma[J]. Clin Transl Oncol,2010,12 (1):15-21.
  • 7Ljungberg B J, Jacobsen J, Rudolfsson S H, et al. Different vascular endothelial growth factor (VEGF), VEGF receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma[J]. BJU Int,2006,98(3):661-667.
  • 8Dobrzanski M J, Reome J B, Hollenbaugh J A, etal. Tcl and Tc2 effector cell therapy elicit long term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses[J]. J Immunol,2004, 172(3) :1380 -1390.
  • 9Nonomura N, Miki T, Yokoyama M, et al. Fas/APO-I- mediated apoptosis of human renal cell carcinoma[J]. Biochem Biophys Res Commun,1996,229(3) :945-951.
  • 10GerharzC D, Ramp U, D6josez M, etal. Resistance to CD95 ( APO 1/Fas ) mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control[J]. Lab Invest,1999,?9(12):1521-1534.

共引文献28

同被引文献52

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部